Search
Supporting faster and more informed decisions for your patients
In the rapidly advancing field of precision oncology, the growing number of targeted treatments brings new hope to your patients. However, waiting weeks for next-generation sequencing (NGS) results, and then possibly not receiving them due to quantity not sufficient (QNS) can diminish this hope. Here is what the Oncomine Dx Express Test, implemented in your pathology laboratory can enable you to do.
Make treatment decisions without waiting for delayed NGS results
Oncomine Dx Express Test delivers genomic profiles in as little as 24 hours—so you can move quickly when timing matters most.
Get results for more patients
How often are you left without answers because of the technology used? Oncomine Dx Express Test is based on amplicon NGS technology, which requires significantly less sample material than other NGS technologies.
Improve care coordination
Oncomine Dx Express Test workflow can be implemented even in smaller and NGS naïve labs, so it can be implemented also in your institution. Having the pathologists and molecular pathology experts just a phone call away and available for multi-disciplinary meetings will help to improve care for your patient. In addition, the sample will stay in-house, ready for additional tests should they be needed.
Ready to speak to a Thermo Fisher Scientific representative?
We will be happy to answer your questions about bringing NGS to your laboratory.
For In Vitro Diagnostic Use.
Not available in all countries.
PMR-004755
Oncomine Dx Express Test (CE-IVD) Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology, the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Oncomine Dx Express Test also detects deletions, insertions, substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.